View More Recent Stories
-
Piper Sandler Reiterates Overweight Rating on Agios Pharma (AGIO)
-
Vertex Pharma (VRTX) Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA
-
Roche Says Obesity Pill’s Side Effects Blunted by Gradual Dosing - Bloomberg
-
Vertex (VRTX) PT Raised to $550 at Oppenheimer
-
Vertex (VRTX) PT Raised to $576 at Wolfe Research
-
Barclays Downgrades Vertex (VRTX) to Equalweight
-
Vertex (VRTX) PT Raised to $535 at Piper Sandler
-
Vertex (VRTX) PT Raised to $600 at H.C. Wainwright
-
Vertex (VRTX) PT Raised to $515 at Evercore ISI
-
Vertex Pharma (VRTX) Misses Q2 EPS by 113c; raises guidance
-
Vertex (VRTX) PT Raised to $376 at Canaccord Genuity
-
Vertex Pharma (VRTX) Announces FDA Acceptance of NDA for Suzetrigine
-
Vertex (VRTX) PT Raised to $500 at TD Cowen
-
10 policies if Trump wins and stock implications: Jefferies
-
Vertex (VRTX) PT Raised to $500 at H.C. Wainwright
-
Vertex Pharma (VRTX) Enters New Extension and Expansion of Drug Discovery Collaboration with Genomics
-
Vertex Pharma (VRTX): Health Canada Grants Marketing Authorization for TRIKAFTA for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare Mutations
-
Vertex Pharma (VRTX) Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for CF
-
Redburn-Atlantic Starts Vertex (VRTX) at Buy
-
Vertex Pharma (VRTX) to Present Positive Results From Ongoing Phase 1/2 Study of VX-880
-
Vertex (VRTX) PT Raised to $550 at Argus
-
Vertex (VRTX) PT Lowered to $421 at RBC Capital
-
Vertex Researchers Awarded 2024 Breakthrough Prize in Life Sciences
